In conjunction with
Lilly’s recent restructuring initiative, the company has named the leaders of its Development Center of Excellence (CoE) and its five business units: oncology, diabetes, established markets, emerging markets, and Elanco animal health.
Tim Garnett, M.D., and
Tom Verhoeven, Ph.D., will lead the CoE within Lilly’s Research Laboratories. Dr. Garnett will have responsibility for medical, regulatory, global product safety, translational medicine and global health outcomes. Dr. Verhoeven will have responsibility for the clinical development organization, product R&D, toxicology/ADME and project management.
John H. Johnson will lead the oncology business unit. He currently serves as chief executive officer of ImClone Systems, which Lilly acquired last year.
Enrique A. Conterno will lead the diabetes business unit. He currently serves as president of Lilly USA.
Bryce D. Carmine will lead the established markets business unit. He currently serves as Lilly's executive vice president of global marketing and sales.
Jacques Tapiero, Lilly's president of the intercontinental region, will lead the emerging markets business unit.
Jeffrey N. Simmons will lead Elanco, the animal health business unit, where he currently serves as president. All appointments will become effective on November 1, 2009.
"These are proven leaders who bring a wealth of experience and knowledge to their respective roles," said John C. Lechleiter, Ph.D., Lilly’s chairman, president and chief executive officer. "Each has demonstrated strong leadership and an ability to get results throughout their business careers. Moving forward, these individuals will play a critical role in the success of Lilly's new operating model."
Dr. Lechleiter outlined the details of the CoE, along with the criteria used to establish Lilly's new business units. The CoE, which has more than 60 molecules in clinical development, will be tasked with streamlining the development of pipeline molecules.
In Oncology, Lilly plans to build its presence, aided by the acquisition of ImClone. Currently, one-third of the company's pipeline consists of molecules to treat various forms of cancer.
Diabetes: Lilly has a dedicated portfolio of commercial products as well as pipeline opportunities. The company is also one of only a few global insulin suppliers.
Lilly's other therapeutic areas, including neuroscience, osteoporosis/bone and cardiovascular, are included in the established markets business unit. This unit will have geographic responsibility for these therapeutic areas in the U.S., Japan, EU, Canada, and Australia/New Zealand. The unit will also host Lilly's global marketing organization.
The Emerging Markets unit will include China, Russia, Brazil, Mexico, South Korea and Turkey. The company plans to increase its presence in these countries and others where strong growth rates for pharmaceuticals are projected over the next decade.
The company remains committed to the Elanco Animal Health unit, which is projected to have double-digit earnings growth during the next five years, bolstered by several recent acquisitions and the launch of its companion animal business.
Sign up today for Contracting & Outsourcing 2009!
contractpharma.com/2009conferenceAlcon has entered into a definitive agreement to acquire
ESBATech AG for $150 million in cash at closing, plus achievement-based R&D payments of as much as $439 million. ESBATech is a Swiss clinical-stage biotechnology company developing a pipeline of single-chain antibody fragment therapeutics for topical and local delivery.
ESBATech has several stable and soluble single-chain antibody fragments in development, as well as a product candidate that has progressed into Phase I and II studies for the treatment of inflammatory ocular diseases.
"Biotechnology offers significant growth opportunities in ophthalmology because it has the potential to deliver therapies with superior efficacy and safety relative to existing approaches," said Sabri Markabi, M.D., Alcon's senior vice president of R&D and chief medical officer. "Combining ESBATech's proprietary antibody fragment technology with our expertise in ophthalmic formulation and capabilities in global development will strengthen Alcon's leadership position in ophthalmology."
The agreement includes all rights to ESBATech’s technology for therapeutic application to the eye. Also, ESBATech’s employees of will join Alcon following the acquisition. The rights to the technology and products for application outside of ophthalmology will be retained by the previous shareholders of ESBATech and spun off into a separate new company, Delenex Therapeutics AG.
Sign up today for Contracting & Outsourcing 2009!
contractpharma.com/2009conference
Marc N. Casper has been appointed president, chief executive officer and a director of
Thermo Fisher Scientific Inc., effective October 15, 2009. Mr. Casper currently serves as executive vice president and chief operating officer and will take over for
Marijn E. Dekkers, who has resigned as president, chief executive officer and a member of the board, to become chief executive officer of Bayer AG.
Chairman Jim Manzi said, “Marc’s strong leadership at Thermo Fisher over the past eight years and his achievements both here and in other companies make him the natural choice to lead the company going forward. We are delighted that he will take on this new role. On behalf of the entire board of directors, we thank Marijn for his dedication to Thermo Fisher over the last nine years. Marijn has led the company through a period of exciting growth and has built a strong foundation for future success.”
Mr. Casper remarked, “I have developed great respect for the knowledge and focus of our employees during my time at Thermo Fisher, and look forward to working with the leadership team and the board in my new role. Thanks to the successful execution of our strategy, demonstrated by our excellent financial track record, we have been able to deliver solid operating performance despite challenging economic conditions. We will work to continue to execute on our strategy for growth and success.”
Sign up today for Contracting & Outsourcing 2009!
contractpharma.com/2009conference
Magazine
